Halozyme Therapeutics, Inc. (0J2O.L)
USD 61.37
(0.79%)
USD 61.37
(0.79%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 636.89 Million USD | 22.29% |
| 2022 | 520.81 Million USD | 43.91% |
| 2021 | 361.89 Million USD | 61.4% |
| 2020 | 224.22 Million USD | 49.04% |
| 2019 | 150.44 Million USD | 6.15% |
| 2018 | 141.72 Million USD | -50.35% |
| 2017 | 285.46 Million USD | 151.54% |
| 2016 | 113.48 Million USD | 7.25% |
| 2015 | 105.81 Million USD | 101.16% |
| 2014 | 52.6 Million USD | 8.34% |
| 2013 | 48.55 Million USD | 17.76% |
| 2012 | 41.23 Million USD | -26.15% |
| 2011 | 55.82 Million USD | 341.72% |
| 2010 | 12.63 Million USD | -5.39% |
| 2009 | 13.35 Million USD | 58.44% |
| 2008 | 8.43 Million USD | 136.91% |
| 2007 | 3.55 Million USD | 553.34% |
| 2006 | 544.75 Thousand USD | 624.01% |
| 2005 | 75.24 Thousand USD | 0.0% |
| 2004 | - USD | 100.0% |
| 2003 | -1298.00 USD | -103.41% |
| 2002 | 38.09 Thousand USD | 331.52% |
| 2001 | 8828.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 173.98 Million USD | 16.15% |
| 2024 Q1 | 149.78 Million USD | -15.73% |
| 2024 Q3 | 240.65 Million USD | 38.32% |
| 2023 FY | 636.89 Million USD | 22.29% |
| 2023 Q1 | 126.97 Million USD | -8.9% |
| 2023 Q2 | 170.96 Million USD | 34.65% |
| 2023 Q4 | 177.74 Million USD | 10.25% |
| 2023 Q3 | 161.21 Million USD | -5.71% |
| 2022 Q4 | 139.37 Million USD | -13.78% |
| 2022 Q3 | 161.65 Million USD | 36.51% |
| 2022 Q1 | 101.35 Million USD | 26.04% |
| 2022 Q2 | 118.42 Million USD | 16.84% |
| 2022 FY | 520.81 Million USD | 43.91% |
| 2021 Q4 | 80.41 Million USD | -17.3% |
| 2021 Q3 | 97.24 Million USD | -14.28% |
| 2021 Q1 | 70.8 Million USD | -25.81% |
| 2021 Q2 | 113.43 Million USD | 60.21% |
| 2021 FY | 361.89 Million USD | 61.4% |
| 2020 Q3 | 59.74 Million USD | 20.75% |
| 2020 FY | 224.22 Million USD | 49.04% |
| 2020 Q4 | 95.43 Million USD | 59.72% |
| 2020 Q2 | 49.48 Million USD | 152.88% |
| 2020 Q1 | 19.56 Million USD | -47.08% |
| 2019 Q1 | 52.3 Million USD | -4.23% |
| 2019 FY | 150.44 Million USD | 6.15% |
| 2019 Q4 | 36.97 Million USD | 54.74% |
| 2019 Q3 | 23.89 Million USD | -35.88% |
| 2019 Q2 | 37.27 Million USD | -28.74% |
| 2018 Q4 | 54.61 Million USD | 119.05% |
| 2018 FY | 141.72 Million USD | -50.35% |
| 2018 Q1 | 27.82 Million USD | -84.72% |
| 2018 Q2 | 34.36 Million USD | 23.53% |
| 2018 Q3 | 24.93 Million USD | -27.46% |
| 2017 Q3 | 55.39 Million USD | 113.38% |
| 2017 Q4 | 182.07 Million USD | 228.66% |
| 2017 Q1 | 22.02 Million USD | -28.96% |
| 2017 Q2 | 25.96 Million USD | 17.88% |
| 2017 FY | 285.46 Million USD | 151.54% |
| 2016 Q3 | 22.71 Million USD | -9.23% |
| 2016 Q2 | 25.02 Million USD | -27.95% |
| 2016 Q1 | 34.73 Million USD | -20.69% |
| 2016 FY | 113.48 Million USD | 7.25% |
| 2016 Q4 | 31 Million USD | 36.45% |
| 2015 Q3 | 14.6 Million USD | -58.57% |
| 2015 Q1 | 12.17 Million USD | -49.76% |
| 2015 Q4 | 43.8 Million USD | 200.0% |
| 2015 FY | 105.81 Million USD | 101.16% |
| 2015 Q2 | 35.24 Million USD | 189.52% |
| 2014 Q3 | 9.46 Million USD | -24.04% |
| 2014 FY | 52.6 Million USD | 8.34% |
| 2014 Q4 | 24.23 Million USD | 156.0% |
| 2014 Q2 | 12.46 Million USD | 93.31% |
| 2014 Q1 | 6.44 Million USD | -28.05% |
| 2013 Q4 | 8.95 Million USD | -41.56% |
| 2013 Q1 | 11.09 Million USD | -47.52% |
| 2013 FY | 48.55 Million USD | 17.76% |
| 2013 Q2 | 13.16 Million USD | 18.71% |
| 2013 Q3 | 15.33 Million USD | 16.41% |
| 2012 Q3 | 5.1 Million USD | -32.92% |
| 2012 Q1 | 7.36 Million USD | 212.93% |
| 2012 Q2 | 7.61 Million USD | 3.32% |
| 2012 Q4 | 21.13 Million USD | 313.88% |
| 2012 FY | 41.23 Million USD | -26.15% |
| 2011 Q1 | 7.53 Million USD | 180.67% |
| 2011 FY | 55.82 Million USD | 341.72% |
| 2011 Q4 | 2.35 Million USD | -89.73% |
| 2011 Q3 | 22.93 Million USD | -0.35% |
| 2011 Q2 | 23.01 Million USD | 205.5% |
| 2010 Q3 | 3.38 Million USD | 8.29% |
| 2010 Q4 | 2.68 Million USD | -20.82% |
| 2010 FY | 12.63 Million USD | -5.39% |
| 2010 Q1 | 3.43 Million USD | -45.32% |
| 2010 Q2 | 3.12 Million USD | -8.91% |
| 2009 Q4 | 6.28 Million USD | 114.74% |
| 2009 Q2 | 1.38 Million USD | -50.11% |
| 2009 Q3 | 2.92 Million USD | 111.88% |
| 2009 FY | 13.35 Million USD | 58.44% |
| 2009 Q1 | 2.76 Million USD | -5.68% |
| 2008 Q4 | 2.93 Million USD | 25.88% |
| 2008 Q2 | 1.39 Million USD | -20.99% |
| 2008 Q1 | 1.76 Million USD | 35.12% |
| 2008 FY | 8.43 Million USD | 136.91% |
| 2008 Q3 | 2.33 Million USD | 66.88% |
| 2007 Q4 | 1.3 Million USD | 48.14% |
| 2007 Q3 | 883.42 Thousand USD | 39.56% |
| 2007 Q2 | 632.99 Thousand USD | -13.76% |
| 2007 Q1 | 733.98 Thousand USD | 90.68% |
| 2007 FY | 3.55 Million USD | 553.34% |
| 2006 Q2 | 103.12 Thousand USD | 104.93% |
| 2006 Q1 | 50.32 Thousand USD | 43.74% |
| 2006 FY | 544.75 Thousand USD | 624.01% |
| 2006 Q4 | 384.92 Thousand USD | 5929.56% |
| 2006 Q3 | 6384.00 USD | -93.81% |
| 2005 Q3 | 15.55 Thousand USD | -36.98% |
| 2005 Q4 | 35 Thousand USD | 125.09% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | 24.67 Thousand USD | 0.0% |
| 2005 FY | 75.24 Thousand USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 100.0% |
| 2004 FY | - USD | 100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q4 | -11.66 Thousand USD | -425.59% |
| 2003 Q3 | 3584.00 USD | -50.8% |
| 2003 FY | -1298.00 USD | -103.41% |
| 2003 Q1 | 2003.00 USD | 238.04% |
| 2003 Q2 | 7284.00 USD | 263.65% |
| 2002 FY | 38.09 Thousand USD | 331.52% |
| 2002 Q4 | -1451.00 USD | -111.06% |
| 2002 Q1 | 26.07 Thousand USD | 0.0% |
| 2002 Q2 | 355.00 USD | -98.64% |
| 2002 Q3 | 13.11 Thousand USD | 3595.21% |
| 2001 FY | 8828.00 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -28653.589% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -210791.391% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 847.385% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -3577.418% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 203579.872% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -4205.07% |
| Imunon, Inc. | -720 Thousand USD | 88556.608% |
| Dynavax Technologies Corporation | 182.11 Million USD | -249.716% |
| Editas Medicine, Inc. | -99.52 Million USD | 739.912% |
| FibroGen, Inc. | 128.9 Million USD | -394.082% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 6757.872% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 210295.38% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 65.525% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 41.73% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -21.604% |
| Verastem, Inc. | -62 Thousand USD | 1027345.161% |
| Zoetis Inc. | 5.83 Billion USD | 89.083% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 92.6% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 1505.167% |
| Homology Medicines, Inc. | -7.22 Million USD | 8910.237% |
| Nektar Therapeutics | 53.47 Million USD | -1090.942% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 218213.699% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 3333.118% |
| Perrigo Company plc | 1.68 Billion USD | 62.099% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -771.655% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 97.599% |
| Illumina, Inc. | 2.74 Billion USD | 76.79% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 95.817% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 87.843% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -6242.282% |
| Waters Corporation | 1.76 Billion USD | 63.837% |
| Biogen Inc. | 7.3 Billion USD | 91.278% |
| Evolus, Inc. | 140.52 Million USD | -353.22% |
| Adicet Bio, Inc. | -6.09 Million USD | 10544.277% |
| bluebird bio, Inc. | -4.03 Million USD | 15903.772% |
| Geron Corporation | -123.5 Million USD | 615.689% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 58.041% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -75.922% |
| Myriad Genetics, Inc. | 476.4 Million USD | -33.688% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 259.705% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 70.638% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 2143.439% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 66.556% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 94.364% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 81.619% |
| OPKO Health, Inc. | 318.12 Million USD | -100.201% |
| Exelixis, Inc. | 1.75 Billion USD | 63.765% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -33.831% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -160.45% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 18.191% |
| Blueprint Medicines Corporation | 236.58 Million USD | -169.203% |
| Insmed Incorporated | 239.63 Million USD | -165.776% |
| TG Therapeutics, Inc. | 219.1 Million USD | -190.675% |
| Incyte Corporation | 3.44 Billion USD | 81.489% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -85.197% |